||Recombinant Human LIFR (Accession # NP_001121143) Met1-Ser833 was produced in Human embryonic kidney cell, HEK293-derived.
|Predicted N Terminal:
||Gln45 predicted: No result obtained, sequencing might be blocked
||Lyophilized from a 0.2 µm filtered solution in PBS.
||Measured by its ability to inhibit LIF-dependent proliferation of TF-1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323.The ED50 for this effect is typically 1-6 µg/mL in the presence of 0.3 ng/mL of recombinant human LIF.
||Recombinant Human LIFR has a calculated MW of 89.4 kDa. In SDS-PAGE migrates as 110-140 kDa, reducing conditions.
||>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).